Establishing secure connection…Loading editor…Preparing document…

Commercialization Agreement

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

COMMERCIALIZATION AGREEMENT

This Commercialization Agreement (the "Agreement") is made as of the day of , (the "Effective Date"), by and between Party A: Name: , Entity Type: , having its principal place of business at ; and Party B: Name: , Entity Type: , having its principal place of business at .

RECITALS

WHEREAS, Party A is the owner or lawful licensee of certain technology, know-how, and intellectual property rights described as follows:

WHEREAS, Party B has expertise, resources and commercial channels sufficient to develop, obtain regulatory approvals for where applicable, manufacture, market and sell products incorporating the technology (the "Product"); and

WHEREAS, the parties wish to set forth the terms under which Party A grants commercialization rights to Party B and the obligations, payments and protections applicable to each party.

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. DEFINITIONS

1.1 "Confidential Information" means all non-public information disclosed by a party relating to the technology, business, operations, financial information, trade secrets, technical data, and other proprietary information, whether disclosed orally, in writing, electronically, or by inspection, that is designated as confidential or that reasonably should be understood to be confidential given the nature of the information and the circumstances of disclosure.

1.2 "Net Sales" means the gross receipts from sales of Product by Party B and its sublicensees less customary and documented deductions including returns, allowances, freight, insurance, and customary trade discounts. Net Sales shall be calculated in accordance with generally accepted accounting principles applied consistently.

1.3 "Territory" means

2. GRANT OF RIGHTS

2.1 License Grant. Subject to the terms and conditions of this Agreement, Party A hereby grants to Party B a license under Party A's Intellectual Property to develop, make, have made, use, sell, offer for sale and import the Product in the Territory and the Field of Use.

2.2 Sublicensing. Party B shall have the right to grant sublicenses to third parties consistent with Party B’s obligations hereunder, provided that Party B remains responsible for all acts and omissions of its sublicensees and delivers to Party A copies of all material sublicenses within thirty (30) days of execution.

2.3 Field of Use. The license granted is limited to the field of use described as:

3. COMMERCIALIZATION OBLIGATIONS

3.1 Diligence. Party B agrees to use commercially reasonable efforts to develop and commercialize the Product in the Territory, including but not limited to preparing a commercialization plan and meeting milestones. Party B shall deliver an initial commercialization plan to Party A within days of the Effective Date and shall update such plan annually.

3.2 Commencement. Party B shall commence significant commercialization activities (including regulatory filings where required or initial commercial sale) no later than day of , .

4. PAYMENTS; ROYALTIES; REPORTS

4.1 Up-Front Payment. Party B shall pay Party A an up-front fee of due within days of the Effective Date.

4.2 Royalties. Party B shall pay Party A a royalty equal to percent (%) of Net Sales of the Product, payable quarterly within forty-five (45) days after the end of each calendar quarter together with a reasonably detailed statement of Net Sales.

4.3 Audit Rights. Party A shall have the right, once per calendar year and upon reasonable notice, to have an independent auditor inspect Party B's relevant books and records to verify royalty calculations. Any underpayment discovered shall be paid with interest at the lesser of 1.5% per month or the maximum rate permitted by law; material underpayments shall also permit audit cost recovery.

5. REGULATORY, QUALITY AND MANUFACTURING

5.1 Regulatory Filings. Party B shall be responsible for obtaining and maintaining all regulatory approvals required to sell the Product in the Territory and shall consult with Party A on material submissions. Party B shall provide Party A with copies of material regulatory correspondence upon request.

5.2 Manufacturing Standards. Products shall be manufactured in accordance with applicable laws and accepted industry manufacturing and quality control standards. Party B shall ensure that all manufacturing sites comply with applicable regulatory requirements and shall notify Party A of material deviations or enforcement actions.

6. INTELLECTUAL PROPERTY

6.1 Ownership. Party A retains all ownership rights in and to the Intellectual Property existing as of the Effective Date. Party B shall not challenge Party A's title to such Intellectual Property. Improvements that are derived from Party A's Intellectual Property shall be owned by subject to any license-back provisions set forth herein.

6.2 Enforcement. The parties shall consult and cooperate regarding the enforcement of the intellectual property rights. Party B shall have the first right, at its election and expense, to enforce such rights against third-party infringers in the Territory; if Party B elects not to proceed, Party A may proceed at its expense.

7. CONFIDENTIALITY

7.1 Confidentiality Obligations. Each party shall maintain in confidence and shall not disclose Confidential Information of the other party except to its employees, contractors and affiliates who have a need to know and who are bound by confidentiality obligations no less restrictive than those set forth herein. Confidential Information shall be exempt from such obligations only if it is or becomes publicly known through no breach, was rightfully received from a third party without confidentiality obligations, or is independently developed without use of the other's Confidential Information.

7.2 Compelled Disclosure. A receiving party may disclose Confidential Information to the extent required by law, regulation, or court order, provided that the receiving party provides prompt notice to the disclosing party and cooperates, at the disclosing party's expense, in any reasonable attempt to obtain protective measures.

8. TERM AND TERMINATION

8.1 Term. This Agreement shall commence on the Effective Date and continue for an initial period of years (the "Initial Term") unless earlier terminated in accordance with this Agreement.

8.2 Termination for Material Breach. Either party may terminate this Agreement upon thirty (30) days written notice if the other party materially breaches any obligation hereunder and fails to cure such breach within the notice period. Termination shall be in addition to all other remedies available at law or in equity.

8.3 Effects of Termination. Upon termination, Party B shall cease further commercialization and, at Party A's election, either sell remaining Product inventory at a mutually agreed discount or return/destroy the inventory. Sections concerning payments, confidentiality, indemnification, ownership and any provisions that by their nature survive shall survive termination.

9. REPRESENTATIONS, WARRANTIES AND DISCLAIMERS

9.1 Mutual Representations. Each party represents and warrants that it has the corporate power and authority to enter into this Agreement and to perform its obligations, and that this Agreement constitutes a valid and binding obligation of such party enforceable in accordance with its terms.

9.2 Party A Warranty. Party A represents and warrants that, to the best of its knowledge, it has the rights necessary to grant the license set forth herein and that the Intellectual Property does not knowingly violate the valid intellectual property rights of any third party. Party A MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

9.3 Party B Warranty. Party B represents and warrants that it will comply with applicable laws and regulatory requirements in carrying out commercialization activities and will not knowingly use the Intellectual Property in a manner that materially misrepresents Party A's rights.

10. INDEMNIFICATION

10.1 Indemnification by Party B. Party B shall indemnify, defend and hold harmless Party A and its officers, directors and affiliates from and against any losses, liabilities, damages and expenses (including reasonable attorneys' fees) arising out of or resulting from Party B's commercialization, manufacture, distribution or sale of the Product, except to the extent caused by Party A's gross negligence or willful misconduct.

10.2 Indemnification by Party A. Party A shall indemnify, defend and hold harmless Party B from third-party claims to the extent arising from Party A's breach of its representations regarding ownership of the Intellectual Property or infringement by the Intellectual Property existing as of the Effective Date.

11. LIMITATION OF LIABILITY

11.1 Except for liabilities arising from willful misconduct, fraud, or a party's indemnification obligations under Section 10, neither party shall be liable to the other for incidental, special, consequential or punitive damages, and aggregate liability shall not exceed the total royalties and fees paid by Party B to Party A under this Agreement in the preceding twelve (12) months.

12. INSURANCE

12.1 Party B shall maintain product liability insurance in commercially reasonable amounts and provide certificates of insurance to Party A upon request. Insurance shall name Party A as an additional insured to the extent reasonably requested by Party A for claims arising out of Party B's commercialization activities.

13. ASSIGNMENT

13.1 Neither party may assign this Agreement in whole or in part without the prior written consent of the other party, except that Party B may assign to an affiliate or to a successor by merger or sale of substantially all of its assets without such consent provided that the assignee assumes all obligations hereunder.

14. NOTICES

15. AMENDMENTS; WAIVER

15.1 Amendment. This Agreement may be amended only by a written instrument signed by authorized representatives of both parties.

15.2 Waiver. No failure or delay by either party in exercising any right shall operate as a waiver of that right unless such waiver is in writing and signed by the waiving party.

16. GOVERNING LAW; DISPUTE RESOLUTION

16.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of without regard to its conflict of laws principles.

16.2 Dispute Resolution. The parties shall attempt in good faith to resolve any disputes arising out of or relating to this Agreement through negotiation between senior executives. If unresolved within sixty (60) days, disputes shall be submitted to arbitration in accordance with commercially reasonable arbitration procedures mutually agreed by the parties. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction.

17. ENTIRE AGREEMENT; SEVERABILITY; COUNTERPARTS

17.1 Entire Agreement. This Agreement, including any exhibits and schedules attached hereto, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions, whether oral or written.

17.2 Severability. If any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not be affected or impaired.

17.3 Counterparts. This Agreement may be executed in counterparts, each of which when executed and delivered shall be an original, and all of which together shall constitute one and the same instrument. Signatures delivered by electronic means shall be effective as originals.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date set forth above.

Party A - Printed Name:

By:

Date:

Party B - Printed Name:

By:

Date:

Enter text✕

What a Commercialization Agreement Is and when it applies

A Commercialization Agreement is a legally binding contract that sets terms for bringing a product, technology, or intellectual property to market. It typically allocates rights and responsibilities between an IP owner and a commercial partner, covering license scope, exclusivity, development milestones, payments or royalties, confidentiality, and termination. Parties use it to coordinate product development, regulatory approvals, manufacturing, distribution, and marketing while protecting core IP and defining revenue-sharing mechanics. Properly drafted, the agreement reduces disputes and clarifies who controls commercialization activities and who bears related costs and liabilities.

Why a clear Commercialization Agreement matters

A well-drafted Commercialization Agreement aligns expectations, protects intellectual property, and defines commercial milestones and payments. It reduces business and legal risk by clarifying ownership, licensing scope, performance obligations, dispute resolution, and confidentiality, enabling parties to pursue market launch with measurable accountability and enforceable remedies.

Why a clear Commercialization Agreement matters

Who typically prepares and signs a Commercialization Agreement

Commercialization Agreements are used by technology licensors, manufacturers, investors, and service providers involved in bringing IP-based products to market.

  • University technology transfer offices and research institutions seeking to license inventions to industry partners.
  • Startup founders and early-stage companies licensing or assigning IP to strategic partners or manufacturers.
  • Corporate business development and legal teams negotiating distribution, manufacturing, or co-development partnerships.

Parties should involve commercial, IP, and legal stakeholders early to ensure alignment on scope, payment terms, and regulatory or reporting obligations.

Essential components to include in a professional Commercialization Agreement

Include clear, enforceable provisions that cover IP rights, commercial scope, financial terms, milestones, compliance, and dispute resolution to reduce uncertainty during commercialization.

Grant and scope

Define the license or assignment precisely: exclusive or nonexclusive, field of use, territory, sublicensing rights, and any retained rights by the licensor; avoid vague or open-ended language.

Financial terms

Specify upfront payments, milestone payments, royalty rates, minimums, reporting cadence, audit rights, and currency; include when taxes or withholding apply and how late payments accrue interest.

Development milestones

List concrete technical, regulatory, and commercial milestones with deliverables, acceptance criteria, and milestone payment triggers tied to objective evidence or approval records.

Intellectual property

Cover ownership of preexisting IP, improvements, and newly created IP; include invention disclosure procedures, prosecution responsibility, and who controls enforcement and related costs.

Confidentiality and data

Set robust confidentiality obligations, permitted disclosures, data handling rules, and breach remedies; include any necessary privacy or HIPAA language for healthcare data.

Termination and remedies

Describe termination for convenience and cause, cure periods, post-termination license scope (e.g., sell-off period), and remedies including injunctive relief, damages, and surviving obligations.

Step-by-step process to complete and execute a Commercialization Agreement

Follow these sequential steps to prepare, negotiate, and finalize the agreement with minimal rework.

  • 01
    Prepare draft: Gather IP records, business terms, and required exhibits.
  • 02
    Internal review: Legal and commercial teams confirm scope and risks.
  • 03
    Negotiate terms: Exchange redlines and confirm milestone and payment mechanics.
  • 04
    Execute and distribute: Obtain authorized signatures and circulate executed copies to stakeholders.

How to set up a digital workflow for the agreement

Use a consistent online workflow to collect signatures, track milestones, and maintain an audit trail for compliance and reporting.

Field Configuration
Signature fields Place full-name, signature, title, and date fields for each party
Conditional clauses Show or hide payment exhibits based on selected license type
Authentication Enable email and optional SMS code signer verification
Audit trail Capture IP address, timestamps, and certificate of completion

Where to file, send, and store executed Commercialization Agreements

Routing and secure storage reduce friction: determine distribution list, where originals are retained, and who updates contract management systems.

  • Primary recipient: Custodial legal or contract repository
  • Counterparty copy: Provide fully executed PDF to each party
  • Corporate record: Upload to contract management or CRM system
  • Backup archive: Store encrypted copy offsite for disaster recovery

Digital signing and integration considerations

Choose a platform that supports secure eSignature workflows, audit trails, and the integrations your organization requires.

  • Authentication methods: Email, SMS, KBA
  • File formats: PDF, DOCX supported
  • Integrations: CRM and cloud storage

Ensure the platform you use supports legal requirements such as ESIGN/UETA compliance, optional HIPAA BAA, and the ability to retain reproducible copies for audits.

Typical deadlines and timing expectations in a Commercialization Agreement

Track contract-specific deadlines for payments, reporting, milestone delivery, termination notices, and IP prosecution activities to avoid breaches and penalties.

Initial payment due:

As specified; often within 30 days of Effective Date

Milestone deadline:

Dates tied to deliverables or regulatory approval

Royalty reporting:

Quarterly or semiannual reports and payments

Termination notice:

Typically 30–90 days' written notice

Patent prosecution actions:

Timelines for prosecution cooperation set by clause

Key project milestones from agreement to market launch

Use a milestone sequence to align technical, regulatory, and commercial tasks with payment triggers and acceptance events.

01

Execution

Agreement signed and Effective Date established

02

Prototype delivery

First technical deliverable submitted for acceptance

03

Regulatory clearance

Obtain required approvals or certifications

04

Commercial launch

Start of distribution and royalty reporting

Security and compliance features to document

Encryption: TLS 1.2/1.3; AES-256 at rest
Audit trail: IP, timestamps, and action history
Certifications: SOC 2 Type II; ISO 27001
HIPAA: BAA available when required
21 CFR Part 11: Supported for regulated workflows
Data privacy: GDPR and CCPA compliance

Penalties and legal risks of an incorrect or incomplete agreement

Assignment failure: May render assignment unenforceable
Lost revenue: Forfeited royalty claims or missed payments
Contract liability: Breach damages and indemnity exposure
Tax penalties: Reporting errors can trigger IRC §6721 fines
Regulatory delay: Missed approvals slow commercialization
Termination costs: Early termination liabilities

Common mistakes to avoid when preparing a Commercialization Agreement

  • Using vague grant language that fails to define field of use or territory, creating future disputes over permitted commercialization activities.
  • Omitting detailed milestone acceptance criteria or objective tests, which leads to disagreements over whether payments are due.
  • Failing to allocate prosecution and enforcement responsibilities for patents and inventions, leaving parties unable to act on infringement.
  • Not specifying audit rights and reporting cadence for royalties, which prevents verification and causes reconciliation conflicts.

Representative scenarios showing common commercialization outcomes

Two practical examples illustrate typical milestone-driven commercialization structures and how payments are triggered by objective events.

Startup license to manufacturer

A biotech startup licenses a method to a manufacturer

  • Milestones include prototype validation and regulatory filing acceptance
  • Payments include an upfront fee, two milestone payments tied to regulatory approvals, and tiered royalties on net sales to align incentives and share commercial risk.

University tech transfer deal

A university grants exclusive rights for a field-limited term

  • Licensee must meet development milestones and report progress quarterly
  • The agreement includes patent prosecution cooperation, milestone payments, sublicense revenue sharing, and a clear reversion clause on material breach.

Comparison of eSignature vendor basics relevant to executing agreements

Common selection criteria include starting price, trial availability, bulk send, audit trails, HIPAA support, and any envelope caps; signNow appears first for comparison.

signNow DocuSign Adobe Sign PandaDoc HelloSign
Starting Price $8/user/mo $15/user/mo $14/user/mo $19/user/mo $15/user/mo
Free Trial 7-day free trial Varies by plan Varies by plan Varies by plan Varies by plan
Bulk Send Yes Yes Yes Yes No
Audit Trail Yes Yes Yes Yes Yes
HIPAA Compliant Yes Yes Yes No No
Envelope Cap No envelope cap 100 envelopes/user/year Varies by plan Varies by plan Varies by plan

Practical tips for accurate and efficient completion

Adopt consistent drafting and execution practices to reduce ambiguity, speed approvals, and support enforceability across jurisdictions.

Use precise IP definitions
Define 'Licensed Technology' and 'Improvements' with concrete examples and patent numbers where applicable. Precise drafting reduces later disputes about scope and helps courts and auditors interpret obligations consistently.
Tie payments to objective evidence
Use measurable acceptance criteria and attach exhibits when payments depend on technical performance or regulatory milestones. This avoids subjective determinations about whether a milestone was achieved and when payment is due.
Document signatory authority
Require representation of authority in the signature block and, for entities, confirm officer title and corporate authorization to bind the organization to avoid later challenges to enforceability.
Maintain an audit trail
Preserve executed PDFs, timestamps, signer authentication logs, and change history. These records support enforcement, audits, and any IP prosecution cooperation needed after execution.

Frequently asked questions about Commercialization Agreements and electronic execution

Answers to common legal and execution questions help teams avoid mistakes and confirm that electronic execution meets legal requirements.


Need help? Contact support

be ready to get more
Join over 28 million airSlate SignNow users